PharmaceuticalsAstraZeneca potassium drug delayed due to manufacturing issues | Reuters
AstraZeneca's new drug for high potassium levels was not approved by the FDA due to a manufacturing issue. Analysts predict the drug will likely be delayed until 2017, after the British-based drug maker issues a complete response letter to the federal drug agency.
Gilead Sciences, Biogen and Jazz Pharmaceuticals said they received subpoenas this year for documents related to relationships with charities that help people afford their products. Bloomberg reported this month that as drug prices rise, pharmaceutical companies contribute to charities to protect against backlash and to keep patients from seeking lower-price alternatives.
Medical devices and equipmentInsurers claim maker of da Vinci surgical robot hid more than 700 injury claims | Bloomberg
Two insurance companies have sued Intuitive Surgical, claiming the manufacturer failed to disclose 700 injury claims when it applied for liability coverage. Intuitive is fighting 86 lawsuits in 22 states. Patients blame surgery complications on its devices.
Information technologyIntermountain Healthcare launches Connect Care telehealth service | (Logan, Utah) Herald News
Residents in Utah and Idaho will now have access to healthcare providers 24 hours a day with the launch of Intermountain Healthcare's Connect Care, a telehealth service connecting patients to physicians via smartphones, tablets and computers.
Safety, quality and clinical practiceAccess to birth control in California still difficult | NPR
Although California Governor Jerry Brown signed a law that allows pharmacists to distribute birth control without a prescription, eight calls to pharmacies around the San Francisco Bay Area revealed no pharmacies were delivering those services. Walgreens, which operates 629 pharmacies in California, said the company is still assessing the law's requirements.
Two Johns Hopkins professors authored a paper in JAMA pushing for more digital coordination of care to treat patients addicted to opioids. The professors, Brendan Saloner and Joshua Sharfstein, write that software-based infrastructure will allow for easier tracking of patient improvement.